{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ghimire S"],"funding":["NHLBI NIH HHS"],"pagination":["105920"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12466150"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["120"],"pubmed_abstract":["Background
Treatments available to prevent progression of virus-induced lung diseases, including coronavirus disease 2019 (COVID-19) are of limited benefit once respiratory failure occurs. The efficacy of approved and emerging cytokine signalling-modulating antibodies is variable and is affected by disease course and patient-specific inflammation patterns. Therefore, understanding the role of inflammation on the viral infectious cycle is critical for effective use of cytokine-modulating agents.Methods
The role of the type 2 cytokine IL-13 on SARS-CoV-2 binding/entry, replication, and host response was investigated in primary HAE cells in vitro and in a model of mouse-adapted SARS-CoV-2 infection in vivo using single-cell and bulk RNA-sequencing approaches. Additionally, the"],"journal":["EBioMedicine"],"pubmed_title":["IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo via eicosanoid signalling."],"pmcid":["PMC12466150"],"funding_grant_id":["R01 HL163024"],"pubmed_authors":["Necker GC","Xue B","Meyerholz DK","Perlman S","Ghimire S","Li K","Zheng J","McCray PB","Pezzulo AA","Gannon RM","Thurman AL","Wohlford-Lenane CL","Gong H"],"additional_accession":[]},"is_claimable":false,"name":"IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo via eicosanoid signalling.","description":"Background
Treatments available to prevent progression of virus-induced lung diseases, including coronavirus disease 2019 (COVID-19) are of limited benefit once respiratory failure occurs. The efficacy of approved and emerging cytokine signalling-modulating antibodies is variable and is affected by disease course and patient-specific inflammation patterns. Therefore, understanding the role of inflammation on the viral infectious cycle is critical for effective use of cytokine-modulating agents.Methods
The role of the type 2 cytokine IL-13 on SARS-CoV-2 binding/entry, replication, and host response was investigated in primary HAE cells in vitro and in a model of mouse-adapted SARS-CoV-2 infection in vivo using single-cell and bulk RNA-sequencing approaches. Additionally, the","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T21:24:07.829Z","creation":"2026-05-01T03:11:10.936Z"},"accession":"S-EPMC12466150","cross_references":{"pubmed":["40957220"],"doi":["10.1016/j.ebiom.2025.105920"]}}